Interviews

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, discusses a study conducted with Takeda and the Harris Poll, focusing on the treatment experiences of patients with metastatic colorectal cancer.

Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a regulatory fix for Stark Law restrictions on mailing oral oncolytics.

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

In this interview, chief operating officer and cofounder of Upfront Healthcare, Carrie Kozlowski, OT, MBA, discusses the integration of artificial intelligence (AI) in health care, emphasizing both opportunities and risks.

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access barriers to persist, said Adam Colborn, JD, of AMCP.

Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care.

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Although most of the innovation in treatment has come in the past decade, new treatments for glaucoma are still being tested, albeit at a slower pace.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

To learn more about the recent bird flu outbreaks, we spoke with Asha Shah, MD, director of infectious diseases and epidemiologist at Stamford Hospital.

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.